Coagulopathy and Fibrinolytic Pathophysiology in COVID-19 and SARS-CoV-2 Vaccination
Coronavirus Disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is frequently complicated by thrombosis. In some cases of severe COVID-19, fibrinolysis may be markedly enhanced within a few days, resulting in fatal bleeding. In the treatment of COVID...
Main Authors: | Shinya Yamada, Hidesaku Asakura |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-03-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/23/6/3338 |
Similar Items
-
Therapeutic Strategies for Disseminated Intravascular Coagulation Associated with Aortic Aneurysm
by: Shinya Yamada, et al.
Published: (2022-01-01) -
Coagulopathy in SARS-CoV-2 Infected Patients: Implication for the Management of COVID-19
by: Getu S, et al.
Published: (2021-07-01) -
Fibrin and Fibrinolytic Enzyme Cascade in Thrombosis: Unravelling the Role
by: Rajni Singh, et al.
Published: (2023-11-01) -
Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry
by: Edward R Kastenhuber, et al.
Published: (2022-03-01) -
Perspective on fibrinolytic therapy in COVID-19: the potential of inhalation therapy against suppressed-fibrinolytic-type DIC
by: Hidesaku Asakura, et al.
Published: (2020-09-01)